Dirjayanto VJ, Audrey J, Simadibrata DM. Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori: Current perspectives and implications. World J Gastroenterol 2024; 30(10): 1280-1286 [PMID: 38596495 DOI: 10.3748/wjg.v30.i10.1280]
Corresponding Author of This Article
Daniel Martin Simadibrata, MD, MSc, Postdoctoral Fellow, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55905, United States. simadibrata.daniel@mayo.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 14, 2024; 30(10): 1280-1286 Published online Mar 14, 2024. doi: 10.3748/wjg.v30.i10.1280
Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori: Current perspectives and implications
Valerie Josephine Dirjayanto, Jessica Audrey, Daniel Martin Simadibrata
Valerie Josephine Dirjayanto, Jessica Audrey, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat 10430, DKI Jakarta, Indonesia
Daniel Martin Simadibrata, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, United States
Daniel Martin Simadibrata, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom
Author contributions: Dirjayanto VJ, Audrey J, and Simadibrata DM reviewed the literature, drafted the original manuscript, and critically revised the manuscript for important intellectual content; all authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All authors have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Daniel Martin Simadibrata, MD, MSc, Postdoctoral Fellow, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55905, United States. simadibrata.daniel@mayo.edu
Received: December 23, 2023 Peer-review started: December 23, 2023 First decision: January 13, 2024 Revised: January 22, 2024 Accepted: February 21, 2024 Article in press: February 21, 2024 Published online: March 14, 2024 Processing time: 82 Days and 14.5 Hours
Core Tip
Core Tip: Vonoprazan-amoxicillin dual therapy with Saccharomyces boulardii (S. boulardii, VAS regimen) emerges as a novel rescue therapy for eradicating Helicobacter pylori (H. pylori). Vonoprazan, a potassium-competitive acid blocker, exhibits superior acid suppression compared to proton pump inhibitors. Notably, dual therapy minimizes the use of an additional antibiotic while maintaining efficacy comparable to traditional triple therapy. This paper highlights the role of S. boulardii, a probiotic, in enhancing the efficacy of Vonoprazan dual therapy by restoring gut microbiota balance, directly affecting H. pylori, and regulating immunomodulation. The VAS regimen emerges as a promising treatment alternative, demonstrating remarkable eradication of H. pylori, even in triple-resistant strains.
